Risks and benefits of withdrawing cyclosporine from the long-term immunosuppression regimen of heart and heart-lung transplant recipients.
Walker
S
S
Imperial College School of Medicine at Harefield Hospital, UK.
Habib
S
S
Thompson
D
D
Khaghani
A
A
Yacoub
M
M
Banner
N
N
D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D016027:Heart Transplantation / Q000276:immunology / Q000502:physiology*; D016041:Heart-Lung Transplantation / Q000276:immunology / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D006435:Renal Dialysis; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D008775:Methylprednisolone